Abstract
Eczema herpeticum (EH) is a disseminated, potentially life-threatening HSV infection in atopic dermatitis (AD) patients. Recently, we showed a type-2 skewed immune response to viruses in EH patients. Dupilumab is a monoclonal antibody targeting the IL-4Ra chain, and therefore acts directly against type-2 inflammation. Molecular investigations examining the impact of dupilumab on the immune defense against viruses are lacking so far. We aimed to analyze the effect of dupilumab on the antiviral response in AD patients with (ADEH+) and without (ADEH-) a history of EH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have